title: Etretinate may work where acitretin fails.
abstract: Acitretin (Ro 10-1670, Neotigason), a second-generation monoaromatic retinoid, is the main acid derivative and active metabolite of etretinate (Ro 10-9359, Tigason). Three patients who were unresponsive to treatment with acitretin but who responded to etretinate are reported. Twenty-nine patients in the U.K. are currently receiving etretinate on a named-patient basis. Possible explanations for the functional discrepancy between the two drugs are discussed.
authors.affiliation: Department of Dermatology, Leicester Royal Infirmary, U.K.
authors.forename: T O
authors.initials: TO
authors.lastname: Bleiker
authors.forename: J F
authors.initials: JF
authors.lastname: Bourke
authors.forename: R A
authors.initials: RA
authors.lastname: Graham-Brown
authors.forename: P E
authors.initials: PE
authors.lastname: Hutchinson
mesh_terms: D017255:Acitretin / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D007644:Darier Disease / Q000188:drug therapy; D005050:Etretinate / Q000627:therapeutic use*; D005260:Female; D006229:Hand Dermatoses / Q000188:drug therapy*; D006801:Humans; D007645:Keratoderma, Palmoplantar / Q000188:drug therapy; D007641:Keratolytic Agents / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D017211:Treatment Failure
chemical_list: D007641:Keratolytic Agents; D005050:Etretinate; D017255:Acitretin